Problem

Haplotype Labs addresses the gap between falling sequencing costs and the practical difficulty of turning population-genetics data into useful prevention. Genetic testing labs, clinicians, and researchers must otherwise deal with expensive sequencing, complex bioinformatics, and bespoke software pipelines; the company states that its goals are to reduce sequencing costs by 50–90%, eliminate bespoke pipelines, and use polygenic risk models to predict, detect, and prevent disease. It also frames the central healthcare problem as the unresolved translation of genetic risk reports into better patient outcomes and longer healthspan.

The main use case is precision preventive care: a genetic testing lab or prevention-focused medical practice uses a patient’s genomic data to identify elevated risk for conditions earlier and tailor screening or intervention accordingly. The economic upside is lower per-person sequencing cost, faster analysis, and potentially lower healthcare costs through earlier, more targeted prevention.

Product / Service

Haplotype Labs is building HaploHub, a SaaS platform for genetic testing labs, concierge medical practices, clinical trials, consumer brands, and payers/providers. The platform is designed to deploy AI and polygenic-risk models using proprietary or more than 4,000 publicly available genetic models, work with genome-wide germ-line or methylation assays, and securely host, manage, and interrogate population genetic data.

HaploHub also provides no-code workflows for common population-genetics operations such as phasing, imputation, and identity-by-descent analysis, along with reporting. Its sequencing-cost proposition is to enable a transition to low-pass sequencing while using downstream inference to preserve useful analytical capability, with the company claiming potential savings of 50–90% and faster deployment than building custom pipelines.

Market

The company sits at the intersection of vertical healthtech SaaS, genomic data infrastructure, clinical decision support, and precision preventive care, specifically the market for polygenic risk-score analysis and genetic testing workflows. The clearest named adjacent competitor is Allelica, whose platform develops, validates, calculates, and reports clinical-grade polygenic risk scores for laboratories, clinicians, and clinical trials. Haplotype Labs appears differentiated in its intended combination of risk-model deployment, population-data management, no-code inference, and low-pass-sequencing economics, although public materials do not establish a definitive competitive moat.

Haplotype Labs was founded in 2024, entered Y Combinator’s Winter 2024 batch, and is listed as active with a one-person team and an open role. PitchBook reports a completed $1.1 million seed round in April 2024 and $1.6 million raised overall, with Y Combinator, 645 Ventures, Brainstorm Ventures, and Soma Capital listed as investors. The reviewed public materials do not disclose customer counts, deployments, or revenue; the company is therefore best characterized as an early-stage, venture-backed business with product development and fundraising traction rather than demonstrated commercial scale.